 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER  Entity.USER(          ) (=>          ) (X           )       (          ) Does DOXYCYCLINE HYCLATE increase or 
decrease the risk of mortality after myocardial infarction?
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER  Entity.USER(Entity.USER) (=>          ) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT 
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(recipient_message) FUNC: {
  "name": "recipient_message",
  "to": "",
  "arguments": {
    "intended_recipient": "FDAHandler",
    "content": "DOXYCYCLINE HYCLATE"
  }
}
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.LLM(          ) (=>FDAHandler) (X           )       (          ) DOXYCYCLINE HYCLATE
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.USER  Entity.USER(          ) (=>FDAHandler) (X           )       (          ) DOXYCYCLINE HYCLATE
 (FDAHandler)  Entity.USER  Entity.USER(Entity.USER) (=>FDAHandler) (X           )       (          ) [CANNOT RESPOND]
 (FDAHandler)  Entity.AGENT 
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(drug_category_search) FUNC: {
  "name": "drug_category_search",
  "to": "",
  "arguments": {
    "category": "antibiotics",
    "sub_categories": [
      "tetracyclines"
    ]
  }
}
*(FDAHandler)  Entity.AGENT  Entity.AGENT(drug_category_search) (=>          ) (X           )       (          ) 
        Below are some relevant extracts for your query:
        -----
        
CONTENT: 
The drugs in category antibiotics with sub-categories tetracyclines include:
MINOCYCLINE, PYLERA, DORYX MPC, DORYX, DOXYCLYCLINE HYCLATE, VIBRAMYCIN CALCIUM, BWELL FIRST AID ANTIBIOTIC, TETRACYTE TOPICAL TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, 
AND TETRACYCLINE HYDROCHLORIDE, ARESTIN, BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE, ACTICLATE, ORACEA, AMZEEQ, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE 
(MONOHYDRATE), L-PHENYLALANINE, QUERCETIN, ILEUM (SUIS), JEJUNUM (SUIS), STOMACH (SUIS), ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG (HEN WHOLE), PROTEUS (MORGANI), 
DOXYCYCLATE HYCLATE, ERAVACYCLINE, SARECYCLINE HYDROCHLORIDE, DOXYCYCLINE, XERAVA, VIBRAMYCIN MONOHYDRATE, EGG ALLERGEN MIX, ZILXI, DOXY 100(TM) DOXYCYCLINE, SOLODYN, VIABECLINE FIRST AID ANTIBIOTIC, 
DOXY 100, DOXYCYCLINE MONOHYDRATE, MEASTEM FIRST AID AND ANTIBIOTIC, DOXYCYCLINE CALCIUM, TYGACIL, APT T3X TETRACYCLINE HYDROCHLORIDE FIRST AID ANTIBIOTIC, TETRACYCLINE HYDROCHLORIDE, BISMUTH 
SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, LYMEPAK, ANISTEM, MINOCIN, TIGECYCLINE, VIBRAMYCIN HYCLATE, TARGADOX, DEMECLOCYCLINE, DEMECLOCYCLINE HYDROCHLORIDE, DOXYCYCLINE 
HYCLATE, OMADACYCLINE, DOXYCYCLINE HYCLATE DELAYED RELEASE, SEYSARA, VIABECLINE, ADENOSINUM TRIPHOSPHORICUM DINATRUM, L-ASPARAGINE (MONOHYDRATE), PHENYLALANINE, QUERCETIN, ILEUM (SUIS), JEJUNUM 
(SUIS), STOMACH (SUIS), CANARY FEATHERS, CATTLE EPITHELIA, CHICKEN FEATHERS, DOG EPITHELIA, DUCK FEATHERS, GERBIL EPITHELIA, GOAT EPITHELIA, GOOSE FEATHERS, GUINEA PIG EPITHELIA, HAMSTER EPITHELIA, 
HOG EPITHELIA, HORSE EPITHELIA, MOUSE EPITHELIA, PARAKEET FEATHERS, RABBIT EPITHELIA, RAT EPITHELIA, STANDARDIZED CAT HAIR, ASCORBICUM ACIDUM, CALCAREA CARBONICA, FERRUM IODATUM, TETRACYCLINE, EGG, 
TETRACYTE TOPICAL, MINOCYCLINE HYDROCHLORIDE, NUZYRA, ACTICLATE CAP, VITASTEM, TETRACYTE TOPICAL - TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE 3 PERCENT A FIRST AID ANTIBIOTIC, and VITASTEM-TETRACYCLINE 
HYDROCHLORIDE.

SOURCE:context


CONTENT: ACTICLATE CAP: clinical_pharmacology: - - - - - Tetracycline ≤4 - - - - - - - - Haemophilus influenzae Tetracycline ≤2 4 ≥8 ≥29 26-28 ≤25 - - - Mycoplasma pneumoniae b Tetracycline - - - - - 
≤2 - - Nocardiae and other aerobic Actinomyces species b Doxycycline ≤1 2-4 ≥8 - - - - - Neisseria gonorrhoeae species c Tetracycline - - - ≥38 31-37 ≤30 ≤0.25 0.5-1 ≥2 Streptococcus pneumoniae 
Doxycycline ≤0.25 0. ACTICLATE CAP: clinical_pharmacology: 5 ≥1 ≥28 25-27 ≤24 - - - Tetracycline ≤1 2 ≥4 ≥28 25-27 ≤24 - - - Vibrio cholerae Doxycycline ≤4 8 ≥16 - - - - - - Tetracycline ≤4 8 ≥16 - - 
- - - - Yersinia pestis Doxycycline ≤4 8 ≥16 - - - - - - Tetracycline ≤4 8 ≥16 - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - ≤1 - ≥2 Doxycycline susceptibility testing interpretive 
criteria for anaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE CAP: clinical_pharmacology: Isolates of 
these species that are susceptible to tetracycline are also considered susceptible to doxycycline. 5 A report of Susceptible (S) indicates that the antimicrobial drug is likely to inhibit growth of 
the pathogen if the antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, 
and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the
drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from 
causing major discrepancies in interpretation. ACTICLATE CAP: clinical_pharmacology: A report of Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if 
the antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use
of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test 5,6,7,8,9,10,11 . 
Standard doxycycline powders should provide the following range of MIC values noted in Table 2 . For the diffusion technique using the 30 mcg doxycycline disk, the criteria noted in Table 2 should be 
achieved. ACTICLATE CAP: clinical_pharmacology: Table 2: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory 
Concentration (mcg per mL) Disk Diffusion (zone diameter mm) Agar Dilution (mcg/ml) Enterococcus faecalis ATCC a 29212 Doxycycline 2 – 8 - - Tetracycline 8-32 - - Escherichia coli ATCC 25922 
Doxycycline 0.5 – 2 18 – 24 - Tetracycline 0.         
SOURCE:ACTICLATE CAP label


CONTENT: DEMECLOCYCLINE HYDROCHLORIDE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with 
antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this 
occurs, patients should contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment 
is started and the blood serology repeated monthly for at least 4 months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be 
performed. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis 
after 3 months. DEMECLOCYCLINE HYDROCHLORIDE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may 
require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class 
drugs in conjunction with penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has
been reported to result in fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, 
Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE HYDROCHLORIDE: precautions: However, 
there has been evidence of oncogenic activity in rats in studies with the related antibiotics oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Although mutagenicity 
studies of demeclocycline HCl have not been conducted, positive results in in vitro mammalian cell assays (i.e., mouse lymphoma and Chinese hamster lung cells) have been reported for related 
antibiotics (tetracyclines HCl and oxytetracycline) (see WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY ). Demeclocycline HCl had no effect on fertility when administered in the diet to male 
and female rats at a daily intake of 45 times the human dose. Pregnancy Teratogenic effects Pregnancy Category D (See WARNINGS ). DEMECLOCYCLINE HYDROCHLORIDE: precautions: Result of animal studies 
indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of 
embryotoxicity has been noted in animals treated early in pregnancy. Nonteratogenic effects (See WARNINGS ) Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing 
Mothers Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue 
nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS ). Pediatric Use Not for use in patients younger than eight years of age .         
SOURCE:DEMECLOCYCLINE HYDROCHLORIDE label


CONTENT: MINOCIN: drug_interactions: Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward 
adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction 
with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. The concurrent use of tetracycline and methoxyflurane
has been reported to result in fatal renal toxicity. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. Administration of isotretinoin should be 
avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri. (See PRECAUTIONS . MINOCIN: drug_interactions: ) Increased risk of 
ergotism when ergot alkaloids or their derivatives are given with tetracyclines.         
SOURCE:MINOCIN label


CONTENT: DOXY 100(TM) DOXYCYCLINE: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at 201°C without melting. The base doxycycline has a high degree of lipid solubility and a
low affinity for calcium binding. It is highly stable in normal human serum. Each 100 mg vial contains: Doxycycline hyclate equivalent to 100 mg doxycycline; ascorbic acid 480 mg; mannitol 300 mg. pH 
of the reconstituted solution (10 mg/mL) is between 1.8 and 3.3. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and 
mannitol in Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY 100(TM) DOXYCYCLINE: description: It is meant for INTRAVENOUS use only after 
reconstitution. Doxycycline hyclate is a yellowish crystalline powder which is chemically designated 4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-de 
monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at 201°C without melting. The base 
doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY 100(TM) DOXYCYCLINE: description: Each 100 mg vial contains: 
Doxycycline hyclate equivalent to 100 mg doxycycline; ascorbic acid 480 mg; mannitol 300 mg. pH of the reconstituted solution (10 mg/mL) is between 1.8 and 3.3.         
SOURCE:DOXY 100(TM) DOXYCYCLINE label


CONTENT: DOXY 100: description: DESCRIPTION Doxycycline hyclate is soluble in water and chars at 201°C without melting. The base doxycycline has a high degree of lipid solubility and a low affinity 
for calcium binding. It is highly stable in normal human serum. Each 100 mg vial contains: Doxycycline hyclate equivalent to 100 mg doxycycline; ascorbic acid 480 mg; mannitol 300 mg. pH of the 
reconstituted solution (10 mg/mL) is between 1.8 and 3.3. Doxycycline for Injection, USP is a sterile, lyophilized powder prepared from a solution of doxycycline hyclate, ascorbic acid and mannitol in
Water for Injection. Doxycycline hyclate is a broad spectrum antibiotic derived from oxytetracycline. DOXY 100: description: It is meant for INTRAVENOUS use only after reconstitution. Doxycycline 
hyclate is a yellowish crystalline powder which is chemically designated 4-(Dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-de monohydrochloride, compound with 
ethyl alcohol (2:1), monohydrate. It has the following structural formula: Doxycycline hyclate is soluble in water and chars at 201°C without melting. The base doxycycline has a high degree of lipid 
solubility and a low affinity for calcium binding. It is highly stable in normal human serum. DOXY 100: description: Each 100 mg vial contains: Doxycycline hyclate equivalent to 100 mg doxycycline; 
ascorbic acid 480 mg; mannitol 300 mg. pH of the reconstituted solution (10 mg/mL) is between 1.8 and 3.3.         
SOURCE:DOXY 100 label


CONTENT: BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: 14 , 7.5 ) Lithium: Increased lithium serum concentrations; measure serum lithium and serum 
creatinine concentrations during therapy. ( 5.14 , 7.6 ) Antacids, Multivitamins or Dairy Products: Decreased absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride 
capsules; do not take concomitantly. ( 7.7 ) Busulfan: Increased busulfan serum concentrations; avoid concomitant use, monitor for busulfan toxicity. ( 7.8 ) CYP inducers and CYP inhibitors: Prolonged
or accelerated half-life of metronidazole or concomitant medications; use with caution. ( 7.9 , 7.10 ) 7. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: 1 
Methoxyflurane Do not administer methoxyflurane to patients taking bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. The concurrent use of tetracycline 
hydrochloride, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, with methoxyflurane has been reported to result in fatal renal toxicity [ see 
Contraindications ( 4.1 ) ] . 7.2 Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole, a component of bismuth subcitrate potassium, metronidazole and 
tetracycline hydrochloride capsules and disulfiram concurrently. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: Bismuth subcitrate potassium, metronidazole
and tetracycline hydrochloride capsules should not be given to patients who have taken disulfiram within the last two weeks [ see Contraindications ( 4.2 ) ] . 7.3 Alcohol Consumption of alcoholic 
beverages or administration of other products containing propylene glycol during treatment with bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and for at least 3 
days afterwards may cause a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) due to the interaction between alcohol or propylene glycol and metronidazole, a 
component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: 
Discontinue alcoholic beverage or other products containing propylene glycol during and for at least 3 days after therapy with bismuth subcitrate potassium, metronidazole and tetracycline 
hydrochloride capsules [ see Contraindications ( 4.3 ) ] . 7.4 Oral Contraceptives Concurrent use of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules with oral 
contraceptive may make oral contraceptives less effective due to an interaction with the tetracycline component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules. 
Breakthrough bleeding has been reported. Women of child-bearing potential should use a different or additional form of contraception while taking bismuth subcitrate potassium, metronidazole and 
tetracycline hydrochloride capsules [ see Warnings and Precautions ( 5.14 ) ] . 7. BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE: drug_interactions: 5 Anticoagulants Bismuth 
subcitrate potassium, metronidazole and tetracycline hydrochloride capsules may alter the anticoagulant effects of warfarin and other oral coumarin anticoagulants. Metronidazole has been reported to 
potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. Tetracycline has been shown to depress plasma prothrombin 
activity. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if bismuth subcitrate potassium, metronidazole and tetracycline 
hydrochloride capsules are administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [ see Warnings and Precautions ( 5.14 ) ] . 7.         
SOURCE:BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, TETRACYCLINE HYDROCHLORIDE label


CONTENT: DEMECLOCYCLINE: precautions: Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, 
patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients
should contact their physician as soon as possible. Laboratory Tests In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment is started and 
the blood serology repeated monthly for at least 4 months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic, should be performed. All 
patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline HCl should have a follow-up serologic test for syphilis after 3 months.
DEMECLOCYCLINE: precautions: Drug Interactions Because tetracyclines have shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of 
their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with 
penicillin. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. The concurrent use of tetracyclines and methoxyflurane has been reported to result 
in fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and by iron-containing preparations. Carcinogenesis, Mutagenesis, Impairment of 
Fertility Long-term studies in animals to evaluate carcinogenic potential of demeclocycline HCl have not been conducted. DEMECLOCYCLINE: precautions: However, there has been evidence of oncogenic 
activity in rats in studies with the related antibiotics oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Although mutagenicity studies of demeclocycline HCl have not 
been conducted, positive results in in vitro mammalian cell assays (i.e., mouse lymphoma and Chinese hamster lung cells) have been reported for related antibiotics (tetracyclines HCl and 
oxytetracycline) (see WARNINGS and ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY ). Demeclocycline HCl had no effect on fertility when administered in the diet to male and female rats at a daily intake of
45 times the human dose. Pregnancy Teratogenic effects Pregnancy Category D (See WARNINGS ). DEMECLOCYCLINE: precautions: Result of animal studies indicate that tetracyclines cross the placenta, are 
found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has been noted in animals treated early in
pregnancy. Nonteratogenic effects (See WARNINGS ) Labor and Delivery The effect of tetracyclines on labor and delivery is unknown. Nursing Mothers Tetracyclines are excreted in human milk. Because of 
the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the 
importance of the drug to the mother (see WARNINGS ). Pediatric Use Not for use in patients younger than eight years of age .         
SOURCE:DEMECLOCYCLINE label


CONTENT: ACTICLATE: clinical_pharmacology: - - - - - Tetracycline ≤4 - - - - - - - - Haemophilus influenzae Tetracycline ≤2 4 ≥8 ≥29 26-28 ≤25 - - - Mycoplasma pneumoniae b Tetracycline - - - - - ≤2 -
- Nocardiae and other aerobic Actinomyces species b Doxycycline ≤1 2-4 ≥8 - - - - - Neisseria gonorrhoeae species c Tetracycline - - - ≥38 31-37 ≤30 ≤0.25 0.5-1 ≥2 Streptococcus pneumoniae Doxycycline
≤0.25 0. ACTICLATE: clinical_pharmacology: 5 ≥1 ≥28 25-27 ≤24 - - - Tetracycline ≤1 2 ≥4 ≥28 25-27 ≤24 - - - Vibrio cholerae Doxycycline ≤4 8 ≥16 - - - - - - Tetracycline ≤4 8 ≥16 - - - - - - Yersinia
pestis Doxycycline ≤4 8 ≥16 - - - - - - Tetracycline ≤4 8 ≥16 - - - - - - Ureaplasma urealyticum Tetracycline - - - - - - ≤1 - ≥2 Doxycycline susceptibility testing interpretive criteria for 
anaerobes, Haemophilus influenzae, Mycoplasma pneumoniae, Neisseria gonorrhoeae , and Ureaplasma urealyticum have not been established. ACTICLATE: clinical_pharmacology: Isolates of these species that
are susceptible to tetracycline are also considered susceptible to doxycycline. 5 A report of Susceptible (S) indicates that the antimicrobial drug is likely to inhibit growth of the pathogen if the 
antimicrobial drug reaches the concentration usually achievable at the site of infection. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the 
microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug 
product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from 
causing major discrepancies in interpretation. ACTICLATE: clinical_pharmacology: A report of Resistant (R) indicates that the antimicrobial drug is not likely to inhibit growth of the pathogen if the 
antimicrobial drug reaches the concentration usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of 
laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test 5,6,7,8,9,10,11 . 
Standard doxycycline powders should provide the following range of MIC values noted in Table 2 . For the diffusion technique using the 30 mcg doxycycline disk, the criteria noted in Table 2 should be 
achieved. ACTICLATE: clinical_pharmacology: Table 2: Acceptable Quality Control Ranges for Doxycycline and Tetracycline a ATCC is the American Type Culture Collection QC Strain Minimal Inhibitory 
Concentration (mcg per mL) Disk Diffusion (zone diameter mm) Agar Dilution (mcg/ml) Enterococcus faecalis ATCC a 29212 Doxycycline 2 – 8 - - Tetracycline 8-32 - - Escherichia coli ATCC 25922 
Doxycycline 0.5 – 2 18 – 24 - Tetracycline 0.         
SOURCE:ACTICLATE label

        -----
        If NONE of the extracts are relevant, try doing a web search with the
        `relevant_search_extracts` tool/function-call
        
 (FDAHandler)  Entity.USER 
 (FDAHandler)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(FDAHandler)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE>
ANSWER: Doxycycline Hyclate is one of the drugs included in the category of antibiotics under the sub-category of tetracyclines. It is a broad-spectrum antibiotic derived from oxytetracycline and is 
highly stable in normal human serum. Doxycycline Hyclate is available in various forms, including intravenous solutions and delayed-release tablets. It is used to treat a wide range of bacterial 
infections and is also indicated for use in certain specific conditions such as chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea, and rickettsial 
infections. The drug is known to be lipid-soluble with a low affinity for calcium binding.

SOURCE: DOXY 100(TM) DOXYCYCLINE label
EXTRACT_START_END: Doxycycline hyclate is soluble ... normal human serum.
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  FDAHandler  Entity.USER(FDAHandler) (=>       LLM) (X           )       (          ) ANSWER: Doxycycline Hyclate is one of 
the drugs included in the category of antibiotics under the sub-category of tetracyclines. It is a broad-spectrum antibiotic derived from oxytetracycline and is highly stable in normal human serum. 
Doxycycline Hyclate is available in various forms, including intravenous solutions and delayed-release tablets. It is used to treat a wide range of bacterial infections and is also indicated for use 
in certain specific conditions such as chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea, and rickettsial infections. The drug is known to be 
lipid-soluble with a low affinity for calcium binding.

SOURCE: DOXY 100(TM) DOXYCYCLINE label
EXTRACT_START_END: Doxycycline hyclate is soluble ... normal human serum.
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) The information provided by FDAHandler 
regarding Doxycycline Hyclate does not mention any direct effects on mortality after myocardial infarction. Doxycycline Hyclate is described as a broad-spectrum antibiotic used to treat various 
bacterial infections and specific conditions such as chronic prostatitis, sinusitis, syphilis, chlamydia, pelvic inflammatory disease, acne, rosacea, and rickettsial infections. There is no mention of
its use or effects in the context of myocardial infarction or its impact on mortality risk associated with myocardial infarction.

Given that the FDA label data does not specify the effect of Doxycycline Hyclate on mortality after myocardial infarction, the answer to the question is DO-NOT-KNOW.
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER 
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(          ) (=>       LLM) (X           )       (          ) 
        Do one of the following:

        1. If you intend to ask a question to FDAAgent:
            Please use the 'add_recipient' tool/function-call
            and specify FDAAgent as your `intended_recipient`.
            DO NOT REPEAT your original message; ONLY specify the 
            `intended_recipient` via this tool/function-call.
        2. If you are ready to have the critic check your answer,
            do so with the `final_answer` tool/function, as I have requested.
        3. If the critic is satisfied and you intend to submit your final answer,
            answer as I have requested, making sure to mark that you are done as usual.

        When you have decided and stated your answer (or lack of one), you must
        ALWAYS specify that you are done using the usual code.

        DO NOT simply acknowldedge these instructions. If you have nothing
        else to say, you MUST EXIT IMMEDIATELY by stating that you are done
        with the usual code (as in #3).
        
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER  Entity.USER(Entity.USER) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>       LLM) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does DOXYCYCLINE HYCLATE increase or decrease the risk of mortality after myocardial infarction?",
    "steps": [
      "I requested information from FDAHandler about Doxycycline Hyclate.",
      "FDAHandler provided information on Doxycycline Hyclate, indicating it is an antibiotic used for various bacterial infections and specific conditions, but there was no mention of its effects on 
mortality after myocardial infarction."
    ],
    "answer": "DO-NOT-KNOW"
  }
}
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) __PASS__:Critic
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(Entity.LLM) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  FDAHandler  Entity.USER(FDAHandler) (=>    Critic) (X           )       (          ) [CANNOT RESPOND]
 (Critic)  Entity.USER  Entity.USER(          ) (=>    Critic) (X           )   FUNC(final_answer) FUNC: {
  "name": "final_answer",
  "to": "",
  "arguments": {
    "question": "Does DOXYCYCLINE HYCLATE increase or decrease the risk of mortality after myocardial infarction?",
    "steps": [
      "I requested information from FDAHandler about Doxycycline Hyclate.",
      "FDAHandler provided information on Doxycycline Hyclate, indicating it is an antibiotic used for various bacterial infections and specific conditions, but there was no mention of its effects on 
mortality after myocardial infarction."
    ],
    "answer": "DO-NOT-KNOW",
    "request": "final_answer"
  }
}
*(Critic)  Entity.AGENT  Entity.AGENT(final_answer) (=>          ) (X           )       (          ) 
        Question: Does DOXYCYCLINE HYCLATE increase or decrease the risk of mortality after myocardial infarction?
        -----
        Reasoning:
        1. I requested information from FDAHandler about Doxycycline Hyclate.
2. FDAHandler provided information on Doxycycline Hyclate, indicating it is an antibiotic used for various bacterial infections and specific conditions, but there was no mention of its effects on 
mortality after myocardial infarction.
        -----
        Final answer: DO-NOT-KNOW
        
 (Critic)  Entity.USER 
 (Critic)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(Critic)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": ""
  }
}
*(Critic)  Entity.LLM  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) <DONE> __PASS__
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Critic  Entity.USER(    Critic) (=>     AGENT) (X           )   FUNC(  feedback) FUNC: {
  "name": "feedback",
  "to": "",
  "arguments": {
    "critique": "",
    "request": "feedback"
  }
}
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(  feedback) (=>          ) (X           )       (          ) Your reasoning is valid, no feedback 
was provided.
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.USER 
 (orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.AGENT  Entity.AGENT(Entity.AGENT) (=>          ) (X           )       (          ) [CANNOT RESPOND]
*(orchestrator-mortality after myocardial infarction-DOXYCYCLINE HYCLATE)  Entity.LLM  Entity.LLM(          ) (=>          ) (X           )       (          ) <DONE> DO-NOT-KNOW

The FDA label data for Doxycycline Hyclate does not specify any information regarding the drug's effect on mortality after myocardial infarction. Therefore, it is not possible to determine whether 
Doxycycline Hyclate increases or decreases the risk of mortality following a myocardial infarction based on the available FDA label data.
